Bristol Myers Squibb critique

Joseph Carlson reviews Barron's pick of Bristol-Myers, warns pipeline risk, and prefers Meta as a higher-quality alternative.

Play episode from 10:29

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!